GFPT1 and medullary thyroid gland carcinoma: ALK fusions have also been descried in medullary thyroid cancer (EML4-ALK and Glutamine:fructose-6-phosphate transaminase 1 (GFPT1)-ALK), with patient response to crizotinib reported in an EML4-ALK patient [33].